Livzon Pharmaceutical Group (HKG:1513, SHE:000513) completed the cancellation of a total of 6,667,795 unexercised share options, a Tuesday Hong Kong bourse filing said.
The options were issued under a 2022 share options incentive scheme, according to the Chinese pharmaceutical company.